JAMP Pharma

Your pharmacy’s generic partner.

We are committed to continuously improving the supply and access to affordable medicines for all Canadians.

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

JAMP Pharma Group Announces the Commercial Launch and Availability of Pr JAMP Ipratropium HFA

JAMP Pharma Group launches Ipratropium HFA, offering the only generic alternative in Canada to the reference product PrAtrovent® HFA (marketed in Canada by Boehringer Ingelheim). With the launch of PrJAMP Ipratropium HFA, the JAMP Pharma Group, a leader in product launches1, broadens its respiratory health offering, giving healthcare professionals and…
August 16, 2024
Uncategorized
JAMP Pharma Group Acquires a Pharmaceutical Manufacturing Facility in Lévis, Quebec

This transaction strengthens JAMP Pharma Group’s position as an industry leader and addresses the increasing demand for locally manufactured pharmaceutical products. Boucherville, Quebec, February 29, 2024 — JAMP Pharma Group, a leading company in the Canadian pharmaceutical industry for over 35 years, announces today, subject to Superior Court approval and…
February 29, 2024
News and events
JAMP Pharma Group announces the commercial launch and product availability for Pr Jamteki TM, the first biosimilar of Stelara® (ustekinumab) in Canada

PrJamtekiTM was the first ustekinumab biosimilar to receive marketing authorization in Canada1. PrJamteki TM is the second biosimilar developed under the exclusive partnership in Canada between JAMP Pharma Group and Alvotech. This second biosimilar launch in 2 years is a very important step, enabling BioJAMPTM to reinforce its leadership role…
March 1, 2024
BIOJAMP, Press release

JAMP Pharma

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

JAMP Pharma Group Announces the Commercial Launch and Availability of Pr JAMP Ipratropium HFA

JAMP Pharma Group Acquires a Pharmaceutical Manufacturing Facility in Lévis, Quebec

JAMP Pharma Group announces the commercial launch and product availability for Pr Jamteki TM, the first biosimilar of Stelara® (ustekinumab) in Canada